Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease with...
— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results...
Lowest satisfaction among medication users, highest for users of non-drug solution TMS Therapy NeuroStar Depression Barometer Infographic FocalData survey results...
-Appointment expected to aid advancement of Theriva’s discovery program and strengthen collaboration with the Institut Catala d’Oncologia (ICO) and the...
BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
PURCHASE, N.Y., May 23, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its...
Submission based on data from the pivotal international Phase III CONTENT clinical program, also recently published in European Urology1CONTENT showed that...
BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
The Company is recognized for its commitment to employees’ well-beingMALVERN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:...
Strategic collaboration supports BEEAH in creating Jawaher Boston Medical District in Sharjah, United Arab EmiratesBoston, MA, May 12, 2023 (GLOBE...
Dr. Rachel Yehuda to Lead Discussions on Therapeutic Application of Psychedelics Additional Featured Speakers Include Dr. Julie Holland, Dr. Carl...
MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical technology...
TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 08, 2023 (GLOBE NEWSWIRE) -- In preclinical studies, PMN310 demonstrated the ability to selectively...
Achievement demonstrates Company’s commitment to rigorous standards for safe and effective productsMALVERN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Neuronetics,...
Management to Host Conference CallBURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company...
Recursion's Pipeline Recursion's internal pipeline as of Q1 2023Entered into agreements to acquire Cyclica and Valence to bolster digital chemistry...
Data highlights the Company’s commitment to advancing TMS and improving patient outcomesMALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Neuronetics,...
PALO ALTO, Calif. and MIAMI, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the...
Campaign features patients’ experiences to support others with depression A Media Snippet accompanying this announcement is available by clicking on the...
Strategic role strengthens NeuroStar® Advanced Therapy commercialization teamMALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a...